

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB Number: 3235-0287  
 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* <b>Michael J. Rider</b>			2. Issuer Name and Ticker or Trading Symbol <b>RESMED INC [RMD ]</b>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last)	(First)	(Middle)	2a. Foreign Trading Symbol			Director 10% Owner			
<b>9001 Spectrum Center Blvd</b>						<input checked="" type="checkbox"/> Officer (give title below) Other (specify below)			
(Street)	<b>CALIFORNIA</b>		<b>92123</b>		<b>Global General Counsel</b>				
(City)	(State)	(Zip)	3. Date of Earliest Transaction (Month/Day/Year) <b>06/01/2026</b>			6. Individual or Joint/Group Filing (Check Applicable Line)			
<b>UNITED STATES</b>						<input checked="" type="checkbox"/> Form filed by One Reporting Person			
(Country)				4. If Amendment, Date of Original Filed (Month/Day/Year)			<input type="checkbox"/> Form filed by More than One Reporting Person		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct(D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
ResMed Common Stock	06/01/2026		F		268.742 (1)	D	\$190.57	9,488 (2)	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr.3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				

Explanation of Responses:

- Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 06/01/2023.
- Includes 66.0288 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan.

/s/ Michael J. Rider, Global General Counsel and Secretary

\*\* Signature of Reporting Person

06/03/2026

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

\*\*

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

**\* Form 4: SEC 1474(03-26)**